Dr. Fekete of New York Medical College received consultation fees from Acadia, Adamas, Impax, Lundbeck, Neurocrine, and Teva.)
Dr. Jankovic, Director of the Parkinson's Disease Center and Movement Disorders Clinic at Baylor College of Medicine, has received research and/or training grants from Adamas, Allergan, Biotie, Civitas/Acorda, Hoffmann-La Roche, Medtronic, Merz, Neurocrine , Nuvelution, Pfizer, Prothena, Psyadon, Revance, and Teva; and has served as a consultant or as an advisory committee member for Adamas, Allergan, Merz, Prothena, Revance, and Teva.)
This article includes discussion of ataxia and fragile X premutation tremor ataxia syndrome. The foregoing terms may include synonyms, similar disorders, variations in usage, and abbreviations.
The author discusses the concept of ataxia, identifies clinical features useful in evaluating ataxic patients, and highlights the broad range of disorders that can present with ataxia as a prominent feature. He presents the differential diagnosis, treatment, and management of ataxic conditions, along with the latest information about the most recently discovered forms of hereditary ataxia.
Historical note and terminology
Ataxia is both a neurologic symptom and a sign of incoordination derived from the Greek verb tassein, meaning “to arrange” or “put in order.” Ataxic movements are poorly organized and usually relate to dysfunction of the cerebellum or its numerous connections with other brain regions (Gilman et al 1981). The Greek physician Herophilus recognized the cerebellum as a distinct brain division, but early studies of cerebellar anatomy and function were not performed until the 17th and 18th centuries (Dow and Moruzzi 1958). The first extensive clinical studies that defined cerebellar syndromes included World War I soldiers who received gunshot wounds to the head (Holmes 1939). Comparative studies between human and animal cerebelli helped define the function of the various cerebellar regions.
Many classification schemes have been developed for hereditary and degenerative disorders that share ataxia as a prominent presenting feature (van de Warrenburg et al 2014). Numerous new genes and their protein products have been identified over the past 15 years, and they should lead to a greater understanding of the pathophysiology and treatments for these diseases in the years ahead.
The term “olivopontocerebellar atrophy” is widely used without clear consensus on specific diagnostic or prognostic implications (Berciano et al 2006). Many cerebellar disorders were originally classified using clinical features, such as "olivopontocerebellar ataxias, types I to V," or pathological descriptions such as "spinopontine atrophy" or "cortical cerebellar degeneration" (Konigsmark and Weiner 1970). These previous classification schemes built on clinical and pathological findings are being replaced by genetic classification based on identification of responsible gene mutations.
Although spasticity can be seen in several types of spinocerebellar ataxias (see Table 1), the term “spastic ataxia” is also occasionally used for the combination of spasticity and ataxia (de Bot et al 2012). The best known example of Charlevoix-Saguenay ataxia is inherited by autosomal recessive transmission due to sacsin gene (SACS) mutations (Engert et al 2000). The first locus for autosomal dominant hereditary spastic ataxia (SAX1) has also been mapped (Meijer et al 2002).
The content you are trying to view is available only to logged in, current MedLink Neurology subscribers.
If you are a subscriber, please log in.
If you are a former subscriber or have registered before, please log in first and then click select a Service Plan or contact Subscriber Services. Site license users, click the Site License Acces link on the Homepage at an authorized computer.